Diabetes Metab J.  2019 Aug;43(4):398-406. 10.4093/dmj.2019.0137.

2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea

Affiliations
  • 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. drkwon@catholic.ac.kr
  • 2Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
  • 3Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.
  • 4Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • 5Division of Endocrinology and Metabolism, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
  • 6Division of Endocrinology and Metabolism, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
  • 7Gwangmyeong Sungae Hospital, Gwangmyeong, Korea.
  • 8Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 9Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
  • 10Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
  • 11Department of Internal Medicine, Korea University College of Medicine, Ansan, Korea.
  • 12Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University College of Medicine, Gwangju, Korea.
  • 13Sejong St. Mary's Diabetes and Endocrine Clinic, Sejong, Korea.
  • 14Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 15Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
  • 16Department of Endocrinology and Metabolism, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
  • 17Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.
  • 18Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea.
  • 19Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Abstract

The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in type 2 diabetes mellitus (T2DM) were updated. The obese and overweight population is increasing steadily in Korea, and half of the Koreans with diabetes are obese. Evidence-based recommendations for weight-loss therapy for obesity management as treatment for hyperglycemia in T2DM were provided. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations.

Keyword

Diabetes mellitus, type 2; Diagnosis; Practice guideline; Therapeutics

MeSH Terms

Blood Pressure
Diabetes Mellitus, Type 2*
Diagnosis
Glucagon-Like Peptide 1
Humans
Hyperglycemia
Korea*
Obesity
Overweight
Glucagon-Like Peptide 1
Full Text Links
  • DMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error